BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee P. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord 2008;23:1696-700. [DOI: 10.1002/mds.22190] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Csoti I, Jost WH, Reichmann H. Parkinson's disease between internal medicine and neurology. J Neural Transm (Vienna) 2016;123:3-17. [PMID: 26298728 DOI: 10.1007/s00702-015-1443-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
2 Zhang J, Zhang J, Wang R. Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev 2018;50:357-68. [PMID: 30227749 DOI: 10.1080/03602532.2018.1497647] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
3 Fasano A, Bove F, Gabrielli M, Ragazzoni E, Fortuna S, Tortora A, Zocco MA, Marconi S, Gasbarrini A, Bentivoglio AR. Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth. Clinical Neuropharmacology 2014;37:91-5. [DOI: 10.1097/wnf.0000000000000034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
4 Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, Barbaro F, Piano C, Fortuna S, Tortora A, Di Giacopo R, Campanale M, Gigante G, Lauritano EC, Navarra P, Marconi S, Gasbarrini A, Bentivoglio AR. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013;28:1241-9. [PMID: 23712625 DOI: 10.1002/mds.25522] [Cited by in Crossref: 159] [Cited by in F6Publishing: 127] [Article Influence: 19.9] [Reference Citation Analysis]
5 Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, Ceravolo MG, Capecci M, Rita Bentivoglio A, Provinciali L. Prevalence of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord. 2011;26:889-892. [PMID: 21520278 DOI: 10.1002/mds.23566] [Cited by in Crossref: 99] [Cited by in F6Publishing: 80] [Article Influence: 9.9] [Reference Citation Analysis]
6 Lahner E, Virili C, Santaguida MG, Annibale B, Centanni M. Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol. 2014;20:10331-10337. [PMID: 25132749 DOI: 10.3748/wjg.v20.i30.10331] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
7 Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR, Ibrahim NM. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson’s disease. PLoS One. 2014;9:e112330. [PMID: 25411976 DOI: 10.1371/journal.pone.0112330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
8 Tan AH, Lim S, Mahadeva S, Loke MF, Tan JY, Ang BH, Chin KP, Mohammad Adnan AF, Ong SMC, Ibrahim AI, Zulkifli N, Lee JK, Lim WT, Teo YT, Kok YL, Ng TY, Tan AGS, Zulkifle IM, Ng CK, Ee SS, Arafin S, Mohamad Shukori K, Vadivelu JS, Marras C, Fox SH, Lang AE. Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. Mov Disord 2020;35:2250-60. [DOI: 10.1002/mds.28248] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
9 Maeda T, Nagata K, Satoh Y, Yamazaki T, Takano D. High prevalence of gastroesophageal reflux disease in Parkinson's disease: a questionnaire-based study. Parkinsons Dis 2013;2013:742128. [PMID: 23476890 DOI: 10.1155/2013/742128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y. Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev 2011;:CD008453. [PMID: 22071847 DOI: 10.1002/14651858.CD008453.pub2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
11 Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Loke MF, Vadivelu JS, Ibrahim N, Yong HS, Tan CT, Fox SH, Lang AE, Lim S. Helicobacter pylori infection is associated with worse severity of Parkinson's disease. Parkinsonism & Related Disorders 2015;21:221-5. [DOI: 10.1016/j.parkreldis.2014.12.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
12 Chiang HL, Lin CH. Altered Gut Microbiome and Intestinal Pathology in Parkinson's Disease. J Mov Disord 2019;12:67-83. [PMID: 31158941 DOI: 10.14802/jmd.18067] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
13 Nyholm D, Hellström PM. Effects of Helicobacter pylori on Levodopa Pharmacokinetics. J Parkinsons Dis 2021;11:61-9. [PMID: 33164946 DOI: 10.3233/JPD-202298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Elfil M, Kamel S, Kandil M, Koo BB, Schaefer SM. Implications of the Gut Microbiome in Parkinson's Disease. Mov Disord 2020;35:921-33. [DOI: 10.1002/mds.28004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 27.0] [Reference Citation Analysis]
15 Dézsi L, Vécsei L. Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. Expert Opinion on Drug Metabolism & Toxicology 2014;10:409-24. [DOI: 10.1517/17425255.2014.878702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
16 Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson's disease. Mov Disord 2014;29:23-32. [PMID: 24151126 DOI: 10.1002/mds.25708] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 10.3] [Reference Citation Analysis]
17 Skjærbæk C, Knudsen K, Horsager J, Borghammer P. Gastrointestinal Dysfunction in Parkinson's Disease. J Clin Med 2021;10:493. [PMID: 33572547 DOI: 10.3390/jcm10030493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
18 Li K, Reichmann H, Ziemssen T. Recognition and treatment of autonomic disturbances in Parkinson’s disease. Expert Review of Neurotherapeutics 2015;15:1189-203. [DOI: 10.1586/14737175.2015.1095093] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
19 Leggio L, Paternò G, Vivarelli S, L'Episcopo F, Tirolo C, Raciti G, Pappalardo F, Giachino C, Caniglia S, Serapide MF, Marchetti B, Iraci N. Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease. Biomolecules 2020;10:E1327. [PMID: 32948090 DOI: 10.3390/biom10091327] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
20 Harsanyiova J, Buday T, Kralova Trancikova A. Parkinson's Disease and the Gut: Future Perspectives for Early Diagnosis. Front Neurosci 2020;14:626. [PMID: 32625058 DOI: 10.3389/fnins.2020.00626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
21 McGee DJ, Lu XH, Disbrow EA. Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease. J Parkinsons Dis 2018;8:367-74. [PMID: 29966206 DOI: 10.3233/JPD-181327] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 14.5] [Reference Citation Analysis]
22 Çamcı G, Oğuz S. Association between Parkinson's Disease and Helicobacter Pylori. J Clin Neurol 2016;12:147-50. [PMID: 26932258 DOI: 10.3988/jcn.2016.12.2.147] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 9.6] [Reference Citation Analysis]
23 Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease. Ageing Res Rev 2018;45:53-61. [PMID: 29705121 DOI: 10.1016/j.arr.2018.04.004] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 29.0] [Reference Citation Analysis]
24 Lee SY. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol. 2012;27:200-211. [PMID: 22098099 DOI: 10.1111/j.1440-1746.2011.06961.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
25 Otero LL, Ruiz VE, Perez Perez GI. Helicobacter pylori: The balance between a role as colonizer and pathogen. Best Practice & Research Clinical Gastroenterology 2014;28:1017-29. [DOI: 10.1016/j.bpg.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
26 Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014;20:12781-12808. [PMID: 25278678 DOI: 10.3748/wjg.v20.i36.12781] [Cited by in CrossRef: 138] [Cited by in F6Publishing: 105] [Article Influence: 23.0] [Reference Citation Analysis]
27 Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter. 2009;14 Suppl 1:58-68. [PMID: 19712170 DOI: 10.1111/j.1523-5378.2009.00699.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
28 Su A, Gandhy R, Barlow C, Triadafilopoulos G. A practical review of gastrointestinal manifestations in Parkinson's disease. Parkinsonism & Related Disorders 2017;39:17-26. [DOI: 10.1016/j.parkreldis.2017.02.029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
29 Gallop A, Weagley J, Paracha SU, Grossberg G. The Role of The Gut Microbiome in Parkinson's Disease. J Geriatr Psychiatry Neurol 2021;34:253-62. [PMID: 34219519 DOI: 10.1177/08919887211018268] [Reference Citation Analysis]
30 Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. Colonic bacterial composition in Parkinson's disease. Mov Disord 2015;30:1351-60. [PMID: 26179554 DOI: 10.1002/mds.26307] [Cited by in Crossref: 494] [Cited by in F6Publishing: 406] [Article Influence: 82.3] [Reference Citation Analysis]
31 Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson’s disease. J Neurol. 2013;260:2974-2980. [PMID: 24002418 DOI: 10.1007/s00415-013-7089-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
32 Liu H, Su W, Li S, Du W, Ma X, Jin Y, Li K, Chen H. Eradication of Helicobacter pylori infection might improve clinical status of patients with Parkinson’s disease, especially on bradykinesia. Clinical Neurology and Neurosurgery 2017;160:101-4. [DOI: 10.1016/j.clineuro.2017.07.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
33 Lolekha P, Sriphanom T, Vilaichone RK. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson's disease patients: A prospective cohort study (HP-PD trial). PLoS One 2021;16:e0251042. [PMID: 33945559 DOI: 10.1371/journal.pone.0251042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Klingelhoefer L, Reichmann H. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nat Rev Neurol 2015;11:625-36. [DOI: 10.1038/nrneurol.2015.197] [Cited by in Crossref: 256] [Cited by in F6Publishing: 213] [Article Influence: 42.7] [Reference Citation Analysis]
35 Keshavarzian A, Engen P, Bonvegna S, Cilia R. The gut microbiome in Parkinson's disease: A culprit or a bystander? Prog Brain Res 2020;252:357-450. [PMID: 32247371 DOI: 10.1016/bs.pbr.2020.01.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
36 Raeder V, Boura I, Leta V, Jenner P, Reichmann H, Trenkwalder C, Klingelhoefer L, Chaudhuri KR. Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience. CNS Drugs 2021;35:215-31. [PMID: 33559846 DOI: 10.1007/s40263-020-00788-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
37 Patrick KL, Bell SL, Weindel CG, Watson RO. Exploring the "Multiple-Hit Hypothesis" of Neurodegenerative Disease: Bacterial Infection Comes Up to Bat. Front Cell Infect Microbiol 2019;9:138. [PMID: 31192157 DOI: 10.3389/fcimb.2019.00138] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
38 Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 2015;21:10609-20. [PMID: 26457021 DOI: 10.3748/wjg.v21.i37.10609] [Cited by in CrossRef: 248] [Cited by in F6Publishing: 200] [Article Influence: 49.6] [Reference Citation Analysis]
39 You H, Mariani LL, Mangone G, Le Febvre de Nailly D, Charbonnier-Beaupel F, Corvol JC. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res 2018;373:111-35. [PMID: 29516217 DOI: 10.1007/s00441-018-2813-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
40 Salat-foix D, Andrews CN, Meddings J, Suchowersky O. Gastrointestinal Symptoms in Parkinson Disease: Clinical Aspects and Management. Can J Neurol Sci 2011;38:557-64. [DOI: 10.1017/s0317167100012099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. The Lancet Neurology 2015;14:625-39. [DOI: 10.1016/s1474-4422(15)00007-1] [Cited by in Crossref: 349] [Cited by in F6Publishing: 142] [Article Influence: 58.2] [Reference Citation Analysis]
42 Bai F, Li X. Association of Helicobacter pylori treatment with Parkinsonism and related disorders: A systematic review and meta-analysis. Life Sci 2021;281:119767. [PMID: 34216625 DOI: 10.1016/j.lfs.2021.119767] [Reference Citation Analysis]
43 Alvarez-Arellano L, Maldonado-Bernal C. Helicobacter pylori and neurological diseases: Married by the laws of inflammation. World J Gastrointest Pathophysiol. 2014;5:400-404. [PMID: 25400983 DOI: 10.4291/wjgp.v5.i4.400] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
44 Dardiotis E, Tsouris Z, Mentis AA, Siokas V, Michalopoulou A, Sokratous M, Dastamani M, Bogdanos DP, Deretzi G, Kountouras J. H. pylori and Parkinson's disease: Meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018;175:16-24. [PMID: 30308319 DOI: 10.1016/j.clineuro.2018.09.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 13.7] [Reference Citation Analysis]
45 Shen X, Yang H, Wu Y, Zhang D, Jiang H. Meta-analysis: Association of Helicobacter pylori infection with Parkinson's diseases. Helicobacter 2017;22:e12398. [DOI: 10.1111/hel.12398] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 10.5] [Reference Citation Analysis]
46 Mridula KR, Borgohain R, Chandrasekhar Reddy V, Bandaru VCh, Suryaprabha T. Association of Helicobacter pylori with Parkinson's Disease. J Clin Neurol 2017;13:181-6. [PMID: 28406585 DOI: 10.3988/jcn.2017.13.2.181] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]